enGene Therapeutics (ENGN) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neumora Therapeutics (NMRA) has outperformed enGene Therapeutics (ENGN) over the past year, losing 75.3% versus a loss of 76.0%. enGene Therapeutics is the larger company by market cap ($119.3 million vs $90.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | NMRA |
|---|---|---|
| Share price | $1.78 | $0.4798 |
| Market cap | $119.29M | $90.15M |
| 1-day change | +2.01% | +2.46% |
| YTD return | -80.29% | -73.20% |
| 1-year return | -75.98% | -75.27% |
| EPS (TTM) | $-2.07 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $3.65 |
| 52-week low | $1.40 | $0.45 |
| Distance from 52-week high | -85.47% | -86.85% |
| Analyst consensus | none | none |
| Avg. price target upside | +84.83% | +1179.70% |
| Average volume | 746.58K | 1.19M |
| Shares outstanding | 67.02M | 187.90M |
| Employees | 81 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Healthcare · Biotechnology · 81 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Healthcare · Biotechnology · 63 employees
ENGN vs NMRA FAQ
Which is bigger, enGene Therapeutics or Neumora Therapeutics?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $119.29M compared with $90.15M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, ENGN or NMRA?
NMRA returned -75.27% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.